RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Clinical trials for RECURRENT ADULT ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ADULT ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT ADULT ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation combo may boost second stem cell transplants for blood cancer relapses
Disease control TerminatedThis study tests adding a precise, low-toxicity radiation to the bone marrow (IMTMI) along with standard chemotherapy before a second donor stem cell transplant. It includes up to 30 adults with blood cancers like leukemia that have returned after a first transplant. The goal is …
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 26, 2026 04:43 UTC
-
New hope for older leukemia patients: drug combo targets hard-to-treat AML
Disease control OngoingThis study tests a new combination of two drugs, nintedanib and azacitidine, in older adults with acute myeloid leukemia (AML) who cannot have or do not want standard intensive chemotherapy. The goal is to find the best dose of nintedanib when given with azacitidine and to see wh…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 26, 2026 04:43 UTC
-
New drug combo shows promise for blood cancers, but cure not yet in sight
Disease control OngoingThis study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works at controlling the disease. About 135 adults with these bloo…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:40 UTC
-
Engineered t cells take aim at Hard-to-Treat leukemias
Disease control OngoingThis early-stage study tests a new type of immunotherapy for people with certain leukemias that have come back or not responded to standard treatment. The therapy uses a patient's own or donor's immune cells that are genetically modified to recognize and attack cancer cells carry…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Smarter CMV strategy may protect stem cell transplant patients
Disease control OngoingThis study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:31 UTC
-
New drug cocktail aims to control tough leukemia
Disease control OngoingThis early-phase study tests the safety and best dose of combining bortezomib, sorafenib, and decitabine for adults with acute myeloid leukemia (AML). It includes older patients who cannot have standard treatment or those whose leukemia has returned. The goal is to find a tolerab…
Matched conditions: RECURRENT ADULT ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC